Periodontal DiseasesNCT06993818
Asprosın And Tumor Necrosıs Factor-α Levels In Type 2 Dıabetıc Chronıc Periodontitis
An observational study of Periodontal Diseases, run by Eda Cetin Ozdemir at 1 site in Turkey (Türkiye).
Trial summary
Periodontal disease is a chronic, multifactorial inflammatory disease in which biochemical and cellular events trigger each other, leading to the destruction of the tissues supporting the teeth . Read more about this study
- Who is it for?
- Ages 18 to 80 years
- Conditions the study is for
- Periodontal Diseases
- What is being tested?
- Gingival Crevicular Fluid and Serum Asprosin
- How many people
- 102 participants
- Where
- 1 siteTurkey (Türkiye)
- Study dates
- 1 Nov 2024to 15 Apr 2025
- Phase
- Observational
- Are there results?
- None posted in the registry
Key requirements
Who can take part, as listed by the sponsor. Only the study team can confirm whether you are eligible, so take this list to your doctor.
- Ages 18 to 80 years
- All sexes
- No healthy volunteers
- Adult, Older adult
Study population: Patients applying to Kahramanmaraş Sütçü İmam University, Faculty of Dentisrty, Department of Periodontology.
Who may be able to join
- The patient must be a volunteer
Who cannot join
- -
Trial locations and contacts
1 site in 1 country.
Turkey (Türkiye)1 site
Kahramanmaraş Sütçü İmam University
Kahramanmaraş
About this study
Official title: Evaluatıon Of Asprosın And Tumor Necrosıs Factor-α Levels In Gıngıval Crevıcular Fluıd And Serum Of Patıents Wıth Controlled And Uncontrolled Type 2 Dıabetıc Chronic Periodontitis
Periodontal disease is a chronic, multifactorial inflammatory disease in which biochemical and cellular events trigger each other, leading to the destruction of the tissues supporting the teeth . The pathogenesis of the disease is a dynamic process that develops as a result of complex interactions between pathogenic bacteria and the host response . There is a bidirectional relationship between diabetes mellitus (DM), which is among the systemic diseases that negatively affect the host immune response, and periodontal disease. In the case of DM, long-term hyperglycemia causes proteins to react irreversibly with glucose, resulting in the formation of advanced glycation end products (AGEs). It is suggested that increased AGE levels increase cytokine secretion against periodontopathogens, exacerbate inflammatory tissue destruction, and may negatively affect biological functions through cell-cell and cell-matrix interactions in the connective tissue.
The present study was conducted to gain further insight into the role of CGF and serum Asprosin level in the pathogenetic processes linking DM and periodontal disease.
Read the detailed description
Periodontal disease is a chronic, multifactorial inflammatory disease in which biochemical and cellular events trigger each other, leading to the destruction of the tissues supporting the teeth . The pathogenesis of the disease is a dynamic process that develops as a result of complex interactions between pathogenic bacteria and the host response . There is a bidirectional relationship between diabetes mellitus (DM), which is among the systemic diseases that negatively affect the host immune response, and periodontal disease . In the case of DM, long-term hyperglycemia causes proteins to react irreversibly with glucose, resulting in the formation of advanced glycation end products (AGEs). It is suggested that increased AGE levels increase cytokine secretion against periodontopathogens, exacerbate inflammatory tissue destruction, and may negatively affect biological functions through cell-cell and cell-matrix interactions in the connective tissue . Periodontitis, a widespread infectious disease, is also considered a systemic inflammation. In the presence of periodontitis, some inflammatory cytokines are produced in periodontal tissues and their levels in the circulation also increase . It has been reported that the levels of Tumor necrosis factor-α (TNF-α), which is considered an acute phase reactant, are increased in the adipose tissue of diabetic rodents. TNF-α has proinflammatory properties and can reduce insulin sensitivity . Studies have shown that diabetic monocytes secrete 24-32 times more TNF-α; this situation is associated with the development and progression of diabetic periodontitis. Adipokines are important molecules secreted from adipose tissue and play a role in various physiological processes such as energy intake, blood pressure, metabolism and inflammation . In 2016, Romere et al. showed that plasma levels of Asprosin, encoded by the Fibrillin-1 gene, increase in the fasting state and decrease after meals. After crossing the blood-brain barrier, the asprosin hormone stimulates the orexigenic (appetite-increasing) AgRP neuron group through a cAMP-dependent pathway activity. Simultaneously, gamma aminobutyric acid-dependent proopiomelanocortin neurons are suppressed, thus increasing appetite, obesity, and ultimately body weight . Asprosin is associated with diseases such as diabetes mellitus, obesity, polycystic ovary syndrome, and cardiovascular diseases . Recent studies have shown that asprosin plays a role in the inflammatory responses of many cell types. Asprosin increases B cell-dependent inflammation by inducing hepatic glucose synthesis and also increases blood glucose levels by inhibiting insulin secretion . Many studies have shown that serum asprosin concentrations in patients with type 2 diabetes mellitus are systemically higher than in healthy controls . However, the authors did not find any studies in the literature evaluating asprosin levels in individuals with type 2 DM and chronic periodontitis. In light of the previous studies summarized above, the present study was conducted to gain more insight into the role of CGF and serum Asprosin levels in the pathogenetic processes linking DM and periodontal disease. This study is the first to examine Asprosin levels in gingival crevicular fluid (GCF) and serum of CP patients with T2DM.
- Conditions
- Periodontal Diseases
- Being tested
- Gingival Crevicular Fluid, Serum Asprosin
- Keywords
- Periodontitis, Diabetes Mellitus, Asprosin levels
- Medical subject headings
- Periodontal Diseases, Periodontitis, Diabetes Mellitus
What participants receive
What participants receive. In a randomised study each person is assigned to one group by chance.
Gingival Crevicular FluidOther
Periodontal clinical parameters and examination of asprosin levels in gingival crevicular fluid and serum samples
Serum AsprosinDiagnostic test
Periodontal clinical parameters and examination of asprosin levels in gingival crevicular fluid and serum samples
| Study group | Role | What they receive |
|---|---|---|
| Control Group: systemically and periodontally healthy control group | Periodontal clinical parameters and examination of asprosin levels in gingival crevicular fluid and serum samples Receives: Other: Gingival Crevicular Fluid; Diagnostic Test: Serum Asprosin | |
| Uncontrolled T2DM-CP: Stage III Grade C Periodontitis, Uncontrolled T2DM group | Periodontal clinical parameters and examination of asprosin levels in gingival crevicular fluid and serum samples Receives: Other: Gingival Crevicular Fluid; Diagnostic Test: Serum Asprosin | |
| Controlled T2DM-CP: Stage III Grade B Periodontitis, Controlled T2DM | Periodontal clinical parameters and examination of asprosin levels in gingival crevicular fluid and serum samples Receives: Other: Gingival Crevicular Fluid; Diagnostic Test: Serum Asprosin | |
| CP: Stage III Grade B Periodontitis group | Periodontal clinical parameters and examination of asprosin levels in gingival crevicular fluid and serum samples Receives: Other: Gingival Crevicular Fluid; Diagnostic Test: Serum Asprosin |
What is being measured
The primary outcome is the main question the study is designed to answer.
Changes in Asprosin Levels in GCF an Serum Samples in periodontal disease
Investigators expect a statistically significant difference between controlled and uncontrolled T2DM and CP patients and healthy individuals in terms of serum and CGF Asprosin levels.
Measured: 6 Mounth
Timeline
From the start of the study to its completion; the mark is today. Estimated dates are the sponsor’s plan.
- First posted29 May 2025
- Study start1 Nov 2024
- Primary completion1 Apr 2025
- Study completion15 Apr 2025
Resources
- Official record on ClinicalTrials.govThe registry entry this page is built from, with its full change history.
- Other trials for Periodontal DiseasesStudies of the same condition, open and under way.
- What the trial phases meanHow a treatment moves from first tests in people to approval.
More details
For doctors and researchers: how the study is designed, who runs it, and its registry IDs.
Study design
- Study type
- Observational
- Observational model
- Other
- Time perspective
- Cross-sectional
- Enrolment
- 102 participants (actual)
Sponsor and investigators
- Lead sponsor
- Eda Cetin Ozdemir
- Sponsor type
- University, hospital or other
- Responsible party
- Sponsor-investigator, Eda Cetin Ozdemir, Kahramanmaras Sutcu Imam University
IDs, dates and publications
- ClinicalTrials.gov ID
- NCT06993818
- Sponsor's protocol ID
- Kahramanmaraş Sütçü İmam Unive
- Status last verified
- May 2025
- First submitted
- 13 May 2025
- Last updated
- 29 May 2025
- Results posted
- No
- Data monitoring committee
- No
- FDA-regulated drug
- No
- FDA-regulated device
- No
- Individual data sharing
- No: I dont want to share
Study at a glance
From the registry record, last updated by the sponsor on 29 May 2025. Recruitment status is as the sponsor reported it: confirm with the study team.
- Official title
- Evaluatıon Of Asprosın And Tumor Necrosıs Factor-α Levels In Gıngıval Crevıcular Fluıd And Serum Of Patıents Wıth Controlled And Uncontrolled Type 2 Dıabetıc Chronic Periodontitis
- ClinicalTrials.gov ID
- NCT06993818
- Acronym / sponsor ID
- Kahramanmaraş Sütçü İmam Unive
- Conditions
- Periodontal Diseases
- Keywords
- Periodontitis, Diabetes Mellitus, Asprosin levels
- Study type
- Observational
- Recruitment status
- Completed
- Enrolment
- 102 participants (actual)
- Lead sponsor
- Eda Cetin OzdemirUniversity, hospital or other
- Study start
- 1 Nov 2024 (actual)
- Primary completion
- 1 Apr 2025 (actual)
- Study completion
- 15 Apr 2025 (actual)
- First posted
- 29 May 2025 (actual)
- Results
- Not posted in the source record
Clinical summary
The research question as the sponsor registered it. This describes what the study plans to test, not what it found.
Periodontal disease is a chronic, multifactorial inflammatory disease in which biochemical and cellular events trigger each other, leading to the destruction of the tissues supporting the teeth . The pathogenesis of the disease is a dynamic process that develops as a result of complex interactions between pathogenic bacteria and the host response . There is a bidirectional relationship between diabetes mellitus (DM), which is among the systemic diseases that negatively affect the host immune response, and periodontal disease. In the case of DM, long-term hyperglycemia causes proteins to react irreversibly with glucose, resulting in the formation of advanced glycation end products (AGEs). It is suggested that increased AGE levels increase cytokine secretion against periodontopathogens, exacerbate inflammatory tissue destruction, and may negatively affect biological functions through cell-cell and cell-matrix interactions in the connective tissue.
The present study was conducted to gain further insight into the role of CGF and serum Asprosin level in the pathogenetic processes linking DM and periodontal disease.
Detailed description
Periodontal disease is a chronic, multifactorial inflammatory disease in which biochemical and cellular events trigger each other, leading to the destruction of the tissues supporting the teeth . The pathogenesis of the disease is a dynamic process that develops as a result of complex interactions between pathogenic bacteria and the host response . There is a bidirectional relationship between diabetes mellitus (DM), which is among the systemic diseases that negatively affect the host immune response, and periodontal disease . In the case of DM, long-term hyperglycemia causes proteins to react irreversibly with glucose, resulting in the formation of advanced glycation end products (AGEs). It is suggested that increased AGE levels increase cytokine secretion against periodontopathogens, exacerbate inflammatory tissue destruction, and may negatively affect biological functions through cell-cell and cell-matrix interactions in the connective tissue . Periodontitis, a widespread infectious disease, is also considered a systemic inflammation. In the presence of periodontitis, some inflammatory cytokines are produced in periodontal tissues and their levels in the circulation also increase . It has been reported that the levels of Tumor necrosis factor-α (TNF-α), which is considered an acute phase reactant, are increased in the adipose tissue of diabetic rodents. TNF-α has proinflammatory properties and can reduce insulin sensitivity . Studies have shown that diabetic monocytes secrete 24-32 times more TNF-α; this situation is associated with the development and progression of diabetic periodontitis. Adipokines are important molecules secreted from adipose tissue and play a role in various physiological processes such as energy intake, blood pressure, metabolism and inflammation . In 2016, Romere et al. showed that plasma levels of Asprosin, encoded by the Fibrillin-1 gene, increase in the fasting state and decrease after meals. After crossing the blood-brain barrier, the asprosin hormone stimulates the orexigenic (appetite-increasing) AgRP neuron group through a cAMP-dependent pathway activity. Simultaneously, gamma aminobutyric acid-dependent proopiomelanocortin neurons are suppressed, thus increasing appetite, obesity, and ultimately body weight . Asprosin is associated with diseases such as diabetes mellitus, obesity, polycystic ovary syndrome, and cardiovascular diseases . Recent studies have shown that asprosin plays a role in the inflammatory responses of many cell types. Asprosin increases B cell-dependent inflammation by inducing hepatic glucose synthesis and also increases blood glucose levels by inhibiting insulin secretion . Many studies have shown that serum asprosin concentrations in patients with type 2 diabetes mellitus are systemically higher than in healthy controls . However, the authors did not find any studies in the literature evaluating asprosin levels in individuals with type 2 DM and chronic periodontitis. In light of the previous studies summarized above, the present study was conducted to gain more insight into the role of CGF and serum Asprosin levels in the pathogenetic processes linking DM and periodontal disease. This study is the first to examine Asprosin levels in gingival crevicular fluid (GCF) and serum of CP patients with T2DM.
Study design
- Observational model
- Other
- Time perspective
- Cross-sectional
- Number of arms
- 4
| Arm | Type | Receives |
|---|---|---|
| Control Group: systemically and periodontally healthy control group | – | Other: Gingival Crevicular Fluid, Diagnostic Test: Serum AsprosinPeriodontal clinical parameters and examination of asprosin levels in gingival crevicular fluid and serum samples |
| Uncontrolled T2DM-CP: Stage III Grade C Periodontitis, Uncontrolled T2DM group | – | Other: Gingival Crevicular Fluid, Diagnostic Test: Serum AsprosinPeriodontal clinical parameters and examination of asprosin levels in gingival crevicular fluid and serum samples |
| Controlled T2DM-CP: Stage III Grade B Periodontitis, Controlled T2DM | – | Other: Gingival Crevicular Fluid, Diagnostic Test: Serum AsprosinPeriodontal clinical parameters and examination of asprosin levels in gingival crevicular fluid and serum samples |
| CP: Stage III Grade B Periodontitis group | – | Other: Gingival Crevicular Fluid, Diagnostic Test: Serum AsprosinPeriodontal clinical parameters and examination of asprosin levels in gingival crevicular fluid and serum samples |
Who may qualify
- Ages
- 18 to 80 years
- Sex
- All
- Healthy volunteers
- Not accepted
- Age groups
- Adult, Older adult
- Study population
- Patients applying to Kahramanmaraş Sütçü İmam University, Faculty of Dentisrty, Department of Periodontology.
Key inclusion criteria (1 listed)
- The patient must be a volunteer
Key exclusion criteria (1 listed)
- -
Eligibility is decided by the study team after screening; this overview does not establish that a patient qualifies. Full inclusion and exclusion criteria.
Interventions
| Intervention | Type | Arms |
|---|---|---|
| Gingival Crevicular FluidPeriodontal clinical parameters and examination of asprosin levels in gingival crevicular fluid and serum samples | Other | CP: Stage III Grade B Periodontitis group, Control Group: systemically and periodontally healthy control group, Controlled T2DM-CP: Stage III Grade B Periodontitis, Controlled T2DM, Uncontrolled T2DM-CP: Stage III Grade C Periodontitis, Uncontrolled T2DM group |
| Serum AsprosinPeriodontal clinical parameters and examination of asprosin levels in gingival crevicular fluid and serum samples | Diagnostic test | CP: Stage III Grade B Periodontitis group, Control Group: systemically and periodontally healthy control group, Controlled T2DM-CP: Stage III Grade B Periodontitis, Controlled T2DM, Uncontrolled T2DM-CP: Stage III Grade C Periodontitis, Uncontrolled T2DM group |
Primary outcome
Changes in Asprosin Levels in GCF an Serum Samples in periodontal disease
Time frame: 6 Mounth
Investigators expect a statistically significant difference between controlled and uncontrolled T2DM and CP patients and healthy individuals in terms of serum and CGF Asprosin levels.
Results and safety
The study is completed, but results are not available in the source record. That does not mean the treatment did or did not work.
Research links
- Official record on ClinicalTrials.govLast updated by the sponsor 29 May 2025.
- Related InfoLink provided by the sponsor.
- Individual participant dataSharing planned: No. I dont want to share
Related trials for Periodontal Diseases
Not yet recruitingObservational study
Periodontal Status and Biomarkers in MASLD
Metabolic Dysfunction-Associated Steatotic Liver Disease (MASLD)
Recruiting
Thermosensitive Hyaluronic Gel With Octenidine as an Adjunctive to Subgingival Instrumentation
Periodontal Disease
Active, not recruitingObservational study
A Retrospective Comparative Evaluation of Omega-3 and Resveratrol Supplementation in Patients With Periodontitis
Periodontitis
Recruiting
Effects of Different Activation Techniques on Antimicrobial Photodynamic Therapy in Apical Periodontitis
Apical Periodontitis, Endodontic Retreatment
Recruiting
Ozone Gel Versus Chlorohexidine Gel as an Adjunct to Non-Surgical Treatment of Stage II Periodontitis Grade B Among Smokers Patients
Ozone Gel, Chlorohexidine Gel
Referral and contact
AzTrials does not enrol participants or take referrals. Contact the study team or a site listed below; they decide who can take part. This study is not recruiting at the moment.
The record lists no contact. Use the official record to reach the sponsor.
1 site in 1 country: see every site and its status.
Questions about this trial
What is this clinical trial studying?
An observational study of Periodontal Diseases, run by Eda Cetin Ozdemir at 1 site in Turkey (Türkiye).
The full registered description is in the About this study section and the official record.
Who may be eligible to take part?
The sponsor lists 1 inclusion and 1 exclusion criteria. Eligibility is decided by the study team after screening, so read the full criteria and contact a listed site.
Is this clinical trial currently recruiting?
The record says: finished, as of the sponsor's last update on 29 May 2025. Status can change between updates, so confirm with the study contact before making plans.
Where is the study taking place?
The record lists 1 site in Turkey (Türkiye). Whether a site is taking part right now should be confirmed with that site. See every site.
What are the possible benefits and risks?
They depend on the study and the treatment, and no study can promise a benefit. The study team explains the known risks during informed consent, before anyone joins; the record itself does not list them.
Are results available for this study?
The study is completed, but results are not available in the source record. That does not mean the treatment did or did not work.
How can a doctor refer a patient or contact the research team?
The record lists no contact. The official record names the sponsor, who can be asked directly. AzTrials does not enrol participants or take referrals.
What does the primary outcome measure?
Changes in Asprosin Levels in GCF an Serum Samples in periodontal disease (time frame: 6 Mounth). It is what the study was designed to measure, not a finding.
Where can I read the original study information?
Does a listing mean the treatment is approved or proven to work?
No. A listing means the study is registered. It does not show that the treatment is safe, works, or is approved by a regulator.
How often is this information updated?
AzTrials copies changed records from ClinicalTrials.gov every night and reloads the whole registry every week. The sponsor last updated this record on 29 May 2025.